Background: The SMILE study is a multi-institutional phase II clinical trial to determine the efficacy and safety of an antiprogestin, onapristone, in combination with fulvestrant as second-line therapy for patients with ER+, PgR+/-, HER2- metastatic breast cancer. This study was terminated early and herein, we report patient characteristics, and outcomes.
Methods: Eligibility criteria included disease progression on ≥2 lines of prior therapy, ECOG performance status ≤ 2, measurable disease per RECIST 1.
Large language models (LLMs) are poised to have a disruptive impact on health care. Numerous studies have demonstrated promising applications of LLMs in medical imaging, and this number will grow as LLMs further evolve into large multimodal models (LMMs) capable of processing both text and images. Given the substantial roles that LLMs and LMMs will have in health care, it is important for physicians to understand the underlying principles of these technologies so they can use them more effectively and responsibly and help guide their development.
View Article and Find Full Text PDFJ Am Coll Health
January 2025
Reviewed empirical studies involving meditation-related interventions for college and university students during the past decade. Based on inclusion criteria, 44 studies were selected for the review and categorized into three major areas: attention, academic performance, and mental health (stress/anxiety). Areas were systemically reviewed and synthesized.
View Article and Find Full Text PDFACS Biomater Sci Eng
January 2025
Improving the utility of biomedical devices implanted in subcutaneous tissue by modulating the innate immune response common to these implants is of great interest to improve their utility. Uncontrolled, most biomedical devices produce an immune reaction known broadly as the foreign body response (FBR), which ultimately isolates the device from the native tissue. The use of electrospun fibers to create a porous surface that promotes tissue in-growth and regeneration represents a new paradigm in FBR modulation.
View Article and Find Full Text PDFBackground: Glioblastoma multiforme (GBM) is an aggressive cancer with poor prognosis, partly due to resistance to the standard chemotherapy treatment, temozolomide (TMZ). Phytocannabinoid cannabidiol (CBD) has exhibited anti-cancer effects against GBM, however, CBD's ability to overcome common resistance mechanisms to TMZ have not yet been investigated. 4'-Fluoro-cannabidiol (4'-F-CBD, or HUF-101/PECS-101) is a derivative of CBD, that exhibits increased activity compared to CBD during in vivo behavioural studies.
View Article and Find Full Text PDF